CLINICAL TRIALS FOR ADVANCED GASTROINTESTINAL STROMAL TUMORS

Trial name: NAVIGATOR

Status: Recruiting

 

Description: Avapritinib is an oral, investigational drug being studied as a potential treatment for people with advanced gastrointestinal stromal tumors (GIST). Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA, protein kinases that play a key role in GIST. NAVIGATOR is a Phase 1 clinical trial that is designed to test the safety and clinical activity of avapritinib in people with advanced GIST.

 

Eligibility:

  • Group 1: People with advanced GIST that has progressed following treatment with imatinib and at least 1 additional tyrosine kinase inhibitor (third-line or later treatment). Please note that Group 1 is fully enrolled and is no longer accepting new patients.
  • Group 2: People with advanced GIST harboring a PDGFRA D842V mutation.
  • Group 3: People with advanced GIST that has progressed following treatment with imatinib (second-line treatment).

A PDGFRA D842V mutation may be identified by your doctor with an archival or new tumor biopsy.

 

More information: Please contact studydirector@blueprintmedicines.com or visit www.navigatorstudy.com or www.clinicaltrials.gov (Identifier: NCT02508532).

 

Trial name: VOYAGER

Status: Recruiting

 

Description: Avapritinib is an oral, investigational drug being studied as a potential treatment for people with advanced GIST. Avapritinib is a potent and selective inhibitor of activated KIT and PDGFRA, protein kinases that play a key role in GIST. VOYAGER is a Phase 3 clinical trial that is designed to test the safety and clinical activity of avapritinib compared to regorafenib in people with advanced GIST.

 

Eligibility:

  • People with advanced GIST that has progressed following treatment with imatinib and 1 or 2 additional tyrosine kinase inhibitors (third-line or fourth-line treatment).

 

More information: Please contact studydirector@blueprintmedicines.com or visit www.clinicaltrials.gov (Identifier: NCT03465722).

 

 

 

CLINICAL TRIAL FOR ADVANCED HEPATOCELLULAR CARCINOMA

Trial name: Phase 1 study of BLU-554 in patients with hepatocellular carcinoma

Status: Recruiting

 

Description: BLU-554 is an oral, investigational drug being studied as a potential treatment for people with advanced FGFR4-activated hepatocellular carcinoma (HCC), a form of liver cancer. BLU-554 is a potent and selective inhibitor of FGFR4, a protein kinase that plays a key role in a subset of patients with HCC. It is estimated that about 30 percent of patients with HCC have tumors with aberrantly activated FGFR4 signaling. This Phase 1 clinical trial is designed to test the safety and clinical activity of BLU-554 in people with FGFR4-activated HCC.

 

Eligibility:

  • Group 1: People with advanced FGFR4-activated HCC who were previously treated with sorafenib, have declined treatment with sorafenib, or do not have access to sorafenib. Please note that Group 1 is fully enrolled and is no longer accepting new patients.
  • Group 2: People with advanced FGFR4-activated HCC who have not been previously treated with a tyrosine kinase inhibitor.

FGFR4 pathway activation may be identified by your doctor with an archival or new tumor biopsy.

 

More information: Please contact studydirector@blueprintmedicines.com or visit www.clinicaltrials.gov (Identifier: NCT02508467).

 

 

 

CLINICAL TRIAL FOR ADVANCED SYSTEMIC MASTOCYTOSIS

Trial name: EXPLORER

Status: Recruiting

 

Description: Avapritinib is an oral, investigational drug being studied as a potential treatment for people with advanced systemic mastocytosis (SM). Avapritinib is a potent and selective inhibitor of activated KIT, including D816V mutant KIT, the driver of disease in nearly all people with SM. EXPLORER is a Phase 1 clinical trial that is designed to test the safety and clinical activity of avapritinib in people with advanced SM.

 

Eligibility:

  • Group 1: People with aggressive SM (ASM)
  • Group 2: People with SM with an associated hematologic neoplasm (SM-AHN)
  • Group 3: People with mast cell leukemia (MCL)

 

More information: Please contact studydirector@blueprintmedicines.com or visit www.clinicaltrials.gov (Identifier: NCT02561988).

 

 

 

CLINICAL TRIAL FOR RET-ALTERED CANCERS

Trial name: ARROW

Status: Recruiting

 

Description: BLU-667 is an oral, investigational drug being studied as a potential treatment for people with advanced RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and other solid tumors. BLU-667 is a potent and selective inhibitor of RET, a protein kinase that plays a key role in subsets of patients across a wide range of cancers. It is estimated that 1 to 2 percent of patients with NSCLC and 60 percent of patients with MTC have RET alterations. ARROW is a Phase 1 clinical trial that is designed to test the safety and clinical activity of BLU-667 in people with RET-altered solid tumors.

 

Eligibility:

  • People with advanced NSCLC, MTC or other solid tumor with a known RET fusion or mutation.

RET alterations may be identified by your doctor with an archival or new tumor biopsy or a blood test.

 

More information: Please contact studydirector@blueprintmedicines.com or visit www.arrowtrial.com or www.clinicaltrials.gov (Identifier: NCT03037385).

 

 

 

Last Updated: April 15, 2018